Links:

About This Episode: The management of type 2 diabetes has long been a challenge, but a new study conducted by researcher Mark Lyngbaek and his colleagues has the potential to add important considerations to the approach to treatment. Titled the "DOSE-EX" randomized clinical trial, their study uncovers the impact of exercise and weight loss on beta-cell function, a key factor in diabetes progression. DOSE-EX is a four-armed randomized trial involving 82 individuals with newly diagnosed type 2 diabetes. The participants were divided into four groups: standard care, calorie restriction, calorie restriction with exercise three times per week, and calorie restriction with exercise six times per week. Over a span of 16 weeks, the researchers assessed the effects of these interventions on beta-cell function using various indicators. The study's findings are incredibly interesting, demonstrating that exercise in combination with diet-induced weight loss leads to a substantial improvement in glucose-stimulated beta-cell function. Importantly, the results indicate the importance of considering both: a) the exercise dose, and b) the methodology of assessing beta-cell function, when evaluating intervention effectiveness. In this episode, Dr. Lyngbaek will elucidate the implications of these findings for the management of type 2 diabetes. We will explore the potential of exercise as a therapeutic tool, its optimal dosage, and the considerations for integrating it into individualized treatment plans. About The Guest: Dr. Mark Lyngbæk is a physician, currently in an introduction position at the Department of Rheumatology and Internal Medicine 2 at Holbæk Hospital, and also a PhD student at the Centre for Physical Activity Research at Rigshospitalet. His research has looked at exercise, beta-cell function and type 2 diabetes. He is supported by a research grant from the Danish Diabetes Academy, which is funded by the Novo Nordisk Foundation (grant number NNF17SA0031406). The Centre for Physical Activity Research is supported by TrygFonden (grants ID 101390, ID 20045, and ID 125132).

Subscribe to PREMIUM